A Phase 3 interventional study of Tedizolid phosphate and Linezolid in Pneumonia, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-27.
Sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 1:1 ratio, randomized, double-blind, double-dummy, multicenter, global Phase 3 study of tedizolid phosphate (TR-701 FA) 200 mg intravenous (IV) once daily for 7 days versus linezolid (Zyvox®, Zyvoxid®, etc) 600 mg IV every 12 hours for 10 days for the treatment of ventilated participants with presumed gram-positive hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), collectively referred to as ventilated nosocomial pneumonia (VNP). Participants with concurrent gram-positive bacteremia are to receive 14 days of active therapy in either treatment arm.
The primary objective is to determine the noninferiority (NI) in all-cause mortality (ACM) within 28 days after randomization of IV tedizolid phosphate compared with IV linezolid in the Intent to Treat (ITT) Analysis Set (NI is declared when the lower bound of the 95% CI > -10).
1,568 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
This study's enrollment of 726 is above the median of 128 across 977 interventional studies indexed under Pneumonia.
Browse Pneumonia studies →Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 65 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
First submitted before Cubist Pharmaceuticals LLC became part of Merck & Co., Inc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
Drug: Tedizolid phosphate
Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.
Drug: Linezolid
Tedizolid phosphate IV 200 mg once daily
Also known as: SIVEXTRO®, TR-701 FA, MK-1986
Linezolid IV 600 mg twice daily
Also known as: ZYVOX®
Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population
The numbers of participants with all-cause mortality within 28 days after randomization was determined in the ITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
Time frame: Up to 28 days
Number of Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
The numbers of participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
Time frame: Up to 28 days
Clinical Response at Test of Cure (TOC) Visit in the Intent-to-Treat (ITT) Population
The clinical response in the ITT population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.
Time frame: 7-14 days after end of therapy - TOC
Clinical Response at Test of Cure (TOC) Visit in the Clinically-Evaluable (CE) Population
The clinical response in the CE population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.
Time frame: 7-14 days after end of therapy - TOC
Number of Methicillin-Susceptible Staphylococcus Aureus (MSSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
The number of MSSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MSSA culture results from respiratory tract or pleural fluid specimens obtained within 36 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
Time frame: Up to 28 days
Number of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population
The number of MRSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MRSA culture results from respiratory tract or pleural fluid specimens obtained within 72 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
Time frame: Up to 28 days
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population
The number of patients in the mITT population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
Time frame: 1-3 days after completing study therapy (Days 8-10 or Days 15-17)
Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiologically-Evaluable 1 (ME-1) Population
The number of patients in the ME-1 population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
Time frame: 1-3 days after completing study therapy (Days 8-10 or Days 15-17)
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (mITT) Population
The number of patients in the mITT population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
Time frame: 7-14 days after end of therapy - TOC
Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiologically-Evaluable 2 (ME-2) Population
The number of patients in the ME-2 population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
Time frame: 7-14 days after end of therapy - TOC
Number of Participants With ≥1 Adverse Events (AEs)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis is based on actual treatment received instead of randomization.
Time frame: Up to 32 days
Number of Participants Discontinuing Study Therapy Due to an Adverse Event (AE)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis was based on actual treatment received and not randomization.
Time frame: Up to 14 days
Ventilated participants with presumed gram-positive hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) were enrolled at study sites located in 34 countries.
| Milestone | Tedizolid | Linezolid |
|---|---|---|
| Started | 366 | 360 |
| Treated | 361 | 357 |
| Completed | 258 | 254 |
| Not completed | 108 | 106 |
| Withdrew: Did not receive study drug | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: At request of sponsor or investigator | 0 | 1 |
| Withdrew: Death | 104 | 99 |
| Withdrew: Transferred to other care facility | 1 | 1 |
The numbers of participants with all-cause mortality within 28 days after randomization was determined in the ITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population | 103 | 95 |
The numbers of participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population | 46 | 49 |
The clinical response in the ITT population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Clinical Success | 206 | 230 |
| Clinical Failure | 144 | 110 |
| Indeterminate | 16 | 20 |
The clinical response in the CE population at the TOC visit (derived from the Investigator's assessment at the EOT and TOC visits) was determined by the investigator to be either: clinical success, clinical failure, or indeterminate. Clinical success was declared when most or all clinical signs were completely resolved, with no new signs of infection, no additional antibiotic therapy was required, and the participant was alive. Indeterminate was declared when the investigator could not determine success or failure. Clinical failure was declared with progression, relapse, or recurrence of new symptoms of infection, or a persistence or insufficient improvement in signs and symptoms of VNP.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Clinical Success | 143 | 146 |
| Clinical Failure | 124 | 97 |
| Indeterminate | 0 | 0 |
The number of MSSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MSSA culture results from respiratory tract or pleural fluid specimens obtained within 36 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Methicillin-Susceptible Staphylococcus Aureus (MSSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population | 31 | 32 |
The number of MRSA-infected participants with all-cause mortality within 28 days after randomization was determined in the mITT population. Participants who had confirmed MRSA culture results from respiratory tract or pleural fluid specimens obtained within 72 hours of study Day 1 were included. Any participants who were lost to follow-up and not known to be alive or deceased by Day 28 were imputed as deceased.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Methicillin-Resistant Staphylococcus Aureus (MRSA)-Infected Participants With All-Cause Mortality in the Microbiological Intent-to-Treat (mITT) Population | 14 | 20 |
The number of patients in the mITT population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiological Intent-to-Treat (mITT) Population | 123 | 166 |
The number of patients in the ME-1 population with a favorable response at EOT was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants With a Favorable Response at End-of-Therapy (EOT) Visit in the Microbiologically-Evaluable 1 (ME-1) Population | 123 | 166 |
The number of patients in the mITT population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (mITT) Population | 117 | 158 |
The number of patients in the ME-2 population with a favorable response at TOC was determined. Favorable response included eradication (absence of the baseline pathogen) and presumed eradication (no source specimen to culture in a participant assessed as a clinical cure by the investigator).
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants With a Favorable Response at Test-of-Cure (TOC) Visit in the Microbiologically-Evaluable 2 (ME-2) Population | 65 | 74 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis is based on actual treatment received instead of randomization.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants With ≥1 Adverse Events (AEs) | 327 | 325 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Safety analysis was based on actual treatment received and not randomization.
| Participants | Tedizolid | Linezolid |
|---|---|---|
| Number of Participants Discontinuing Study Therapy Due to an Adverse Event (AE) | 4 | 3 |
Collected over Up to 32 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tedizolid | 101/357 (28.3%) | 129/357 (36.1%) | 176/357 (49.3%) |
| Linezolid | 103/361 (28.5%) | 149/361 (41.3%) | 175/361 (48.5%) |
| Event | Tedizolid | Linezolid |
|---|---|---|
| Cardiac arrestCardiac disorders | 21/357 | 16/361 |
| Septic shockInfections and infestations | 16/357 | 18/361 |
| Brain oedemaNervous system disorders | 13/357 | 7/361 |
| Multiple organ dysfunction syndromeGeneral disorders | 8/357 | 12/361 |
| Cardio-respiratory arrestCardiac disorders | 7/357 | 6/361 |
| Acute kidney injuryRenal and urinary disorders | 5/357 | 7/361 |
| SepsisInfections and infestations | 6/357 | 5/361 |
| PneumoniaInfections and infestations | 4/357 | 6/361 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/357 | 6/361 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/357 | 5/361 |
| Event | Tedizolid | Linezolid |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 56/357 | 51/361 |
| DiarrhoeaGastrointestinal disorders | 34/357 | 49/361 |
| HypokalaemiaMetabolism and nutrition disorders | 38/357 | 34/361 |
| ConstipationGastrointestinal disorders | 31/357 | 28/361 |
| HypotensionVascular disorders | 27/357 | 25/361 |
| Urinary tract infectionInfections and infestations | 26/357 | 20/361 |
| Decubitus ulcerSkin and subcutaneous tissue disorders | 22/357 | 26/361 |
| VomitingGastrointestinal disorders | 19/357 | 15/361 |
| HypertensionVascular disorders | 19/357 | 14/361 |
| Age, Continuous(Years) | Tedizolid | Linezolid | Total |
|---|---|---|---|
| Mean | 58.1 ± 18.41 | 58.7 ± 17.44 | 58.4 ± 17.93 |
| Sex: Female, Male(Participants) | Tedizolid | Linezolid | Total |
|---|---|---|---|
| Female | 117 | 106 | 223 |
| Male | 249 | 254 | 503 |
| Ethnicity (NIH/OMB)(Participants) | Tedizolid | Linezolid | Total |
|---|---|---|---|
| Hispanic or Latino | 65 | 61 | 126 |
| Not Hispanic or Latino | 290 | 289 | 579 |
| Unknown or Not Reported | 11 | 10 | 21 |
| Race (NIH/OMB)(Participants) | Tedizolid | Linezolid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 68 | 70 | 138 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 11 | 14 |
| White | 269 | 258 | 527 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 23 | 19 | 42 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2014 to primary completion in Jun 2018, 53 months.
Results were first posted in Jun 2019, 1 year after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Pneumonia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 32. This study's 53 months is above that.
Counting every sponsor, half of 67 studies reached it within 17 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedizolid phosphate
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →